Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 6 de 6
Filter
1.
Can J Anaesth ; 69(9): 1129-1138, 2022 09.
Article in English | MEDLINE | ID: mdl-35877041

ABSTRACT

PURPOSE: Intraoperative tranexamic acid (TXA) is used to reduce blood loss and the need for transfusions following total hip arthroplasty (THA) and total knee arthroplasty (TKA). Despite evidence in literature and local practice protocols supporting TXA as a part of standard of care for joint arthroplasty, TXA administration is underutilized. We aimed to use group-facilitated audit and feedback as the foundation of a knowledge translation strategy to increase TXA use for THA and TKA procedures. METHODS: Anesthesiologists consented to receive two data reports summarizing their individual rates of TXA use and postoperative blood transfusions compared with site peers. Variables collected included patient demographics, TXA usage, and the frequency and volume of red blood cell transfusions administered in the 72-hr postoperative period. The facilitated feedback session discussed report findings and focused on factors contributing to local practice patterns and opportunities for change. RESULTS: Tranexamic acid use increased for THA procedures at the intervention site from 66.6 to 74.4% (absolute change, 7.9%; 95% confidence interval [CI], 2.4 to 13.3). Likewise, TXA use for TKA procedures increased from 62.4 to 82.3% (absolute change, 19.9%; 95% CI 15.0 to 25.0). CONCLUSIONS: Physicians and their teams were able to review their practice data on TXA utilization, reflect on differences compared with evidence-based guidelines, discuss findings with peers, and identify opportunities for improvement. The intervention increased the use of TXA for both TKA and THA and shifted the dosage to better align with evidence-based practice guidelines.


RéSUMé: OBJECTIF : L'acide tranexamique (ATX) peropératoire est utilisé pour réduire les pertes sanguines et les besoins transfusionnels après les arthroplasties totales de la hanche (ATH) et du genou (ATG). Malgré les données probantes et les protocoles de pratique locaux appuyant l'utilisation d'ATX dans le cadre de la norme de soins en cas d'arthroplastie, l'administration de cet agent est sous-utilisée. Notre objectif était d'utiliser l'audit et la rétroaction facilités par le groupe comme base d'une stratégie d'application des connaissances afin d'accroître l'utilisation de l'ATX lors des ATH et ATG. MéTHODE: Les anesthésiologistes ont consenti à recevoir deux rapports de données résumant leurs taux individuels d'utilisation d'ATX et de transfusions sanguines postopératoires par rapport à leurs pairs au sein du même établissement. Les variables recueillies comprenaient les données démographiques des patients, l'utilisation d'ATX et la fréquence et le volume des transfusions d'érythrocytes administrées au cours d'une période postopératoire de 72 heures. La séance de rétroaction facilitée a porté sur les conclusions du rapport et s'est concentrée sur les facteurs contribuant aux habitudes de pratique locales et aux possibilités de changement. RéSULTATS: L'utilisation d'acide tranexamique a augmenté pour les procédures d'ATH au site d'intervention, passant de 66,6 % à 74,4 % (variation absolue, 7,9 %; intervalle de confiance [IC] à 95 %, 2,4 à 13,3). De même, l'utilisation d'ATX pour les procédures d'ATG est passée de 62,4 % à 82,3 % (variation absolue, 19,9 %; IC 95 %, 15,0 à 25,0). CONCLUSION: Les médecins et leurs équipes ont pu passer en revue leurs données de pratique sur l'utilisation d'ATX, réfléchir aux différences par rapport aux lignes directrices fondées sur des données probantes, discuter des résultats avec leurs pairs et identifier les possibilités d'amélioration. L'intervention a augmenté l'utilisation d'ATX pour l'ATG et l'ATH et a modifié la posologie pour mieux s'aligner sur les lignes directrices de pratique fondées sur des données probantes.


Subject(s)
Antifibrinolytic Agents , Arthroplasty, Replacement, Hip , Arthroplasty, Replacement, Knee , Tranexamic Acid , Administration, Intravenous , Antifibrinolytic Agents/therapeutic use , Blood Loss, Surgical/prevention & control , Feedback , Humans , Tranexamic Acid/therapeutic use
2.
Can J Hosp Pharm ; 75(1): 34-40, 2022.
Article in English | MEDLINE | ID: mdl-34987261

ABSTRACT

BACKGROUND: Patients with diabetes are more likely to undergo a surgical procedure than the rest of the population, and it is well established that preoperative hyperglycemia is associated with adverse surgical outcomes. However, it is currently unknown what factors increase the odds of preoperative hyperglycemia in people with diabetes. OBJECTIVE: To identify patient characteristics that increase the risk of preoperative hyperglycemia. METHODS: This retrospective case-control study compared 100 patients with preoperative hyperglycemia on admission for elective surgery at South Health Campus in Calgary, Alberta (blood glucose > 10.9 mmol/L) with 200 controls who did not have preoperative hyperglycemia on admission for elective surgery (blood glucose ≤ 10.9 mmol/L). Multivariate logistic regression was used to identify risk factors for preoperative hyperglycemia. RESULTS: In the univariate analysis, age, number of comorbidities, increasing glycated hemoglobin (HbA1c), type of diabetes, type of procedure, and diabetes medications (non-insulin, insulin, both, or none) were associated with increased odds of preoperative hyperglycemia (p < 0.05). However, in the adjusted analysis, only increasing HbA1c (odds ratio [OR] 1.69, 95% confidence interval [CI] 1.36-2.12) and type 1 diabetes (OR 4.24, 95% CI 1.11-16.21, relative to type 2 diabetes) were associated with preoperative hyperglycemia. CONCLUSIONS: These results can help clinicians to identify patients who may be at increased risk of hyperglycemia before an elective procedure. They also allow for treatment of those who would benefit most from additional guidance with regard to preoperative glucose management.


CONTEXTE: Les patients diabétiques sont plus susceptibles que le reste de la population de subir une intervention chirurgicale, et il est bien connu que l'hyperglycémie préopératoire est associée à des résultats chirurgicaux indésirables. Cependant, on ignore actuellement quels facteurs augmentent ce risque chez les personnes atteintes de diabète. OBJECTIF: Déterminer les caractéristiques des patients qui augmentent le risque d'hyperglycémie préopératoire. MÉTHODES: Cette étude cas-témoins rétrospective a comparé 100 patients présentant une hyperglycémie préopératoire à l'admission pour une intervention chirurgicale non urgente au South Health Campus de Calgary, en Alberta (glycémie > 10,9 mmol/L) avec 200 témoins qui n'en présentaient pas (glycémie ≤ 10,9 mmol/L). La détermination des facteurs de risque d'hyperglycémie préopératoire s'est faite par régression logistique multivariée. RÉSULTATS: Dans l'analyse univariée, l'âge, le nombre de comorbidités, l'augmentation du taux d'hémoglobine glyquée (HbA1c), le type de diabète, le type d'intervention et les médicaments contre le diabète (non-insuline, insuline, les deux ou aucun) étaient associés à un risque accru d'hyperglycémie préopératoire (p < 0,05). Cependant, dans l'analyse ajustée, seuls l'augmentation de l'HbA1c (rapport de cotes [RC] 1,69; intervalle de confiance [IC] à 95 % 1,36­2,12) et le diabète de type 1 (RC 4,24; IC à 95 % 1,11­16,21, par rapport au diabète de type 2) étaient associés à une hyperglycémie préopératoire. CONCLUSIONS: Ces résultats peuvent aider les cliniciens à repérer les patients qui pourraient présenter un plus grand risque d'hyperglycémie avant une intervention non urgente. Ils permettent également de traiter ceux qui bénéficieraient le plus de conseils supplémentaires en matière de gestion préopératoire de la glycémie.

3.
JAMA ; 320(23): 2448-2460, 2018 12 18.
Article in English | MEDLINE | ID: mdl-30561481

ABSTRACT

Importance: Harms and benefits of opioids for chronic noncancer pain remain unclear. Objective: To systematically review randomized clinical trials (RCTs) of opioids for chronic noncancer pain. Data Sources and Study Selection: The databases of CENTRAL, CINAHL, EMBASE, MEDLINE, AMED, and PsycINFO were searched from inception to April 2018 for RCTs of opioids for chronic noncancer pain vs any nonopioid control. Data Extraction and Synthesis: Paired reviewers independently extracted data. The analyses used random-effects models and the Grading of Recommendations Assessment, Development and Evaluation to rate the quality of the evidence. Main Outcomes and Measures: The primary outcomes were pain intensity (score range, 0-10 cm on a visual analog scale for pain; lower is better and the minimally important difference [MID] is 1 cm), physical functioning (score range, 0-100 points on the 36-item Short Form physical component score [SF-36 PCS]; higher is better and the MID is 5 points), and incidence of vomiting. Results: Ninety-six RCTs including 26 169 participants (61% female; median age, 58 years [interquartile range, 51-61 years]) were included. Of the included studies, there were 25 trials of neuropathic pain, 32 trials of nociceptive pain, 33 trials of central sensitization (pain present in the absence of tissue damage), and 6 trials of mixed types of pain. Compared with placebo, opioid use was associated with reduced pain (weighted mean difference [WMD], -0.69 cm [95% CI, -0.82 to -0.56 cm] on a 10-cm visual analog scale for pain; modeled risk difference for achieving the MID, 11.9% [95% CI, 9.7% to 14.1%]), improved physical functioning (WMD, 2.04 points [95% CI, 1.41 to 2.68 points] on the 100-point SF-36 PCS; modeled risk difference for achieving the MID, 8.5% [95% CI, 5.9% to 11.2%]), and increased vomiting (5.9% with opioids vs 2.3% with placebo for trials that excluded patients with adverse events during a run-in period). Low- to moderate-quality evidence suggested similar associations of opioids with improvements in pain and physical functioning compared with nonsteroidal anti-inflammatory drugs (pain: WMD, -0.60 cm [95% CI, -1.54 to 0.34 cm]; physical functioning: WMD, -0.90 points [95% CI, -2.69 to 0.89 points]), tricyclic antidepressants (pain: WMD, -0.13 cm [95% CI, -0.99 to 0.74 cm]; physical functioning: WMD, -5.31 points [95% CI, -13.77 to 3.14 points]), and anticonvulsants (pain: WMD, -0.90 cm [95% CI, -1.65 to -0.14 cm]; physical functioning: WMD, 0.45 points [95% CI, -5.77 to 6.66 points]). Conclusions and Relevance: In this meta-analysis of RCTs of patients with chronic noncancer pain, evidence from high-quality studies showed that opioid use was associated with statistically significant but small improvements in pain and physical functioning, and increased risk of vomiting compared with placebo. Comparisons of opioids with nonopioid alternatives suggested that the benefit for pain and functioning may be similar, although the evidence was from studies of only low to moderate quality.


Subject(s)
Analgesics, Opioid/therapeutic use , Chronic Pain/drug therapy , Adult , Analgesics, Opioid/adverse effects , Anti-Inflammatory Agents, Non-Steroidal/therapeutic use , Anticonvulsants/therapeutic use , Antidepressive Agents, Tricyclic/therapeutic use , Cannabinoids/therapeutic use , Chronic Pain/physiopathology , Female , Humans , Male , Middle Aged , Pain Measurement , Randomized Controlled Trials as Topic , Vomiting/chemically induced
4.
Pain ; 156(9): 1615-1619, 2015 Sep.
Article in English | MEDLINE | ID: mdl-26020224

ABSTRACT

The Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMMPACT) has recommended that trialists evaluating treatments for chronic pain should consider reporting 9 patient-important outcome domains. We examined the extent to which clinical trials evaluating the effect of opioids for chronic non-cancer pain (CNCP) report outcome domains recommended by IMMPACT. We systematically searched electronic databases for English-language studies that randomized patients with CNCP to receive an opioid or a non-opioid control. In duplicate and independently, reviewers established the eligibility of each identified study and recorded all reported outcome domains from eligible trials. We conducted a priori regression analyses to explore factors that may be associated with IMMPACT-recommended outcome domains. Among 156 eligible trials, reporting of IMMPACT-recommended outcome domains was highly variable, ranging from 99% for pain to 7% for interpersonal functioning. Recently published trials were more likely to report the effect of treatment on physical functioning, emotional functioning, role functioning, sleep and fatigue, and participant disposition. Trials for which the corresponding author was from North America were more likely to report treatment effects on physical functioning and participant ratings of improvement and satisfaction with treatment. Trials published in higher impact journals were more likely to report treatment effects on emotional function, but less likely to report participant ratings of improvement and satisfaction with treatment. Most IMMPACT domains showed an increased rate of reporting over time, although many patient-important outcome domains remained unreported by over half of all trials evaluating the effects of opioids for CNCP.


Subject(s)
Analgesics, Opioid/therapeutic use , Chronic Pain/drug therapy , Clinical Trials as Topic , Treatment Outcome , Databases, Bibliographic/statistics & numerical data , Humans
5.
Med Educ ; 49(2): 186-92, 2015 Feb.
Article in English | MEDLINE | ID: mdl-25626749

ABSTRACT

OBJECTIVES: Clinical skills expertise can be advanced through accessible and cost-effective video-based observational practice activities. Previous findings suggest that the observation of performances of skills that include flaws can be beneficial to trainees. Observing the scope of variability within a skilled movement allows learners to develop strategies to manage the potential for and consequences associated with errors. This study tests this observational learning approach on the development of the skills of central line insertion (CLI). METHODS: Medical trainees with no CLI experience (n = 39) were randomised to three observational practice groups: a group which viewed and assessed videos of an expert performing a CLI without any errors (F); a group which viewed and assessed videos that contained a mix of flawless and errorful performances (E), and a group which viewed the same videos as the E group but were also given information concerning the correctness of their assessments (FA). All participants interacted with their observational videos each day for 4 days. Following this period, participants returned to the laboratory and performed a simulation-based insertion, which was assessed using a standard checklist and a global rating scale for the skill. These ratings served as the dependent measures for analysis. RESULTS: The checklist analysis revealed no differences between observational learning groups (grand mean ± standard error: [20.3 ± 0.7]/25). However, the global rating analysis revealed a main effect of group (d.f.2,36 = 4.51, p = 0.018), which describes better CLI performance in the FA group, compared with the F and E groups. CONCLUSIONS: Observational practice that includes errors improves the global performance aspects of clinical skill learning as long as learners are given confirmation that what they are observing is errorful. These findings provide a refined perspective on the optimal organisation of skill education programmes that combine physical and observational practice activities.


Subject(s)
Clinical Competence , Education, Medical, Graduate/methods , Learning , Videotape Recording , Adult , Checklist , Female , Humans , Male
6.
Can J Anaesth ; 52(1): 88-93, 2005 Jan.
Article in English | MEDLINE | ID: mdl-15625263

ABSTRACT

PURPOSE: We examine two cases of prolonged neuromuscular blockade (NMB) after cardiac surgery. To the best of our knowledge, these are the first reported cases of complete paralysis lasting more than ten hours after surgery. CLINICAL FEATURES: We attribute the extended durations of NMB (more than ten hours) to high doses of NMB drugs in combination with magnesium sulphate and moderate renal failure. Advanced age, hepatic disease, aminoglycoside exposure, hypocalcemia, and possible interaction between rocuronium and pancuronium may have played minor roles. CONCLUSION: We should avoid administering large doses of NMB agents, even in the context of planned postoperative ventilation. If NMB is not monitored intraoperatively in patients who are at risk of prolonged NMB, then train-of-four response should be measured in the intensive care unit. Adequate sedation should be provided until proper recovery of neuromuscular function is documented.


Subject(s)
Cardiac Surgical Procedures , Neuromuscular Blockade/adverse effects , Acute Kidney Injury/complications , Aged , Aminoglycosides/adverse effects , Androstanols/adverse effects , Anesthesia Recovery Period , Aorta/surgery , Aortic Valve/surgery , Coronary Artery Bypass , Drug Interactions , Female , Heart Valve Prosthesis Implantation , Humans , Hypocalcemia/complications , Liver Diseases/complications , Magnesium Sulfate/adverse effects , Mitral Valve/surgery , Neuromuscular Nondepolarizing Agents/adverse effects , Pancuronium/adverse effects , Paralysis/chemically induced , Rocuronium
SELECTION OF CITATIONS
SEARCH DETAIL